share_log

ARS: Annual Report to Security Holders

ARS: Annual Report to Security Holders

ARS：年度報告
美股sec公告 ·  04/26 07:13
Moomoo AI 已提取核心訊息
Cingulate Inc., a biopharmaceutical company, reported its financial results for the fiscal year ended December 31, 2023. The company, which focuses on developing products for conditions like ADHD, has not generated revenue and continues to incur losses. For 2023, the net loss was $23.5 million, an increase from the $17.7 million loss in 2022. The company's cash and cash equivalents stood at $52,416 at year-end, down from $5.3 million the previous year. Cingulate raised funds through various means, including a public offering, private placement, and debt conversion. The company's future plans involve seeking additional capital to support operations and product development. Cingulate's stock is listed on the NASDAQ Capital Market, and it faces the risk of delisting if it fails to meet the exchange's continued listing requirements. The company's financial statements have been prepared on a going concern basis, but there is substantial doubt about its ability to continue due to its financial condition.
Cingulate Inc., a biopharmaceutical company, reported its financial results for the fiscal year ended December 31, 2023. The company, which focuses on developing products for conditions like ADHD, has not generated revenue and continues to incur losses. For 2023, the net loss was $23.5 million, an increase from the $17.7 million loss in 2022. The company's cash and cash equivalents stood at $52,416 at year-end, down from $5.3 million the previous year. Cingulate raised funds through various means, including a public offering, private placement, and debt conversion. The company's future plans involve seeking additional capital to support operations and product development. Cingulate's stock is listed on the NASDAQ Capital Market, and it faces the risk of delisting if it fails to meet the exchange's continued listing requirements. The company's financial statements have been prepared on a going concern basis, but there is substantial doubt about its ability to continue due to its financial condition.
生物製藥公司Cingulate Inc. 公佈了截至2023年12月31日的財年財務業績。該公司專注於開發針對注意力缺陷多動障礙等疾病的產品，但尚未創造收入，並且繼續蒙受損失。2023年，淨虧損爲2350萬美元，較2022年的1770萬美元虧損有所增加。截至年底，該公司的現金及現金等價物爲52,416美元，低於去年的530萬美元。Cingulate通過各種方式籌集資金，包括公開發行、私募和債務轉換。該公司的未來計劃包括尋求額外資金以支持運營和產品開發。Cingulate的股票在納斯達克資本市場上市，如果未能滿足該交易所的持續上市要求，它將面臨退市的風險。該公司的財務報表是在持續經營的基礎上編制的，但由於其財務狀況，其持續經營能力存在重大疑問。
生物製藥公司Cingulate Inc. 公佈了截至2023年12月31日的財年財務業績。該公司專注於開發針對注意力缺陷多動障礙等疾病的產品，但尚未創造收入，並且繼續蒙受損失。2023年，淨虧損爲2350萬美元，較2022年的1770萬美元虧損有所增加。截至年底，該公司的現金及現金等價物爲52,416美元，低於去年的530萬美元。Cingulate通過各種方式籌集資金，包括公開發行、私募和債務轉換。該公司的未來計劃包括尋求額外資金以支持運營和產品開發。Cingulate的股票在納斯達克資本市場上市，如果未能滿足該交易所的持續上市要求，它將面臨退市的風險。該公司的財務報表是在持續經營的基礎上編制的，但由於其財務狀況，其持續經營能力存在重大疑問。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息